- Home
- Publications
- Publication Search
- Publication Details
Title
Novel STAT 3 inhibitors for treating gastric cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 25, Issue 9, Pages 1023-1031
Publisher
Informa UK Limited
Online
2016-06-20
DOI
10.1080/13543784.2016.1195807
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies
- (2015) A. L. Wong et al. ANNALS OF ONCOLOGY
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies
- (2015) Michinori Ogura et al. CANCER SCIENCE
- The nationwide genomic screening project for gastrointestinal cancer in Japan (GI-SCREEN): Simultaneous identification of KRAS, NRAS, BRAF, and PIK3CA mutation in advanced colorectal cancer (aCRC) (GI-SCREEN 2013-01).
- (2015) Kohei Shitara et al. JOURNAL OF CLINICAL ONCOLOGY
- Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)
- (2015) Lara Brambilla et al. Molecular Oncology
- Suppression of cancer relapse and metastasis by inhibiting cancer stemness
- (2015) Youzhi Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop
- (2015) Zhengyan Yang et al. Oncotarget
- Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
- (2015) Do-Youn Oh et al. Cancer Research and Treatment
- Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
- (2014) Johanna C. Bendell et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention
- (2014) Ailian Xiong et al. Cancers
- OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells
- (2013) Mi-Jung Kim et al. CANCER LETTERS
- Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial
- (2013) Shuichi Hironaka et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Activation of STAT3 in Human Gastric Cancer Cells via Interleukin (IL)-6-Type Cytokine Signaling Correlates with Clinical Implications
- (2013) Zhengguang Wang et al. PLoS One
- A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases
- (2013) F Hayakawa et al. Blood Cancer Journal
- STAT3-Driven Upregulation of TLR2 Promotes Gastric Tumorigenesis Independent of Tumor Inflammation
- (2012) Hazel Tye et al. CANCER CELL
- Enhancement of leptin receptor signaling by SOCS3 deficiency induces development of gastric tumors in mice
- (2012) K Inagaki-Ohara et al. ONCOGENE
- STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
- (2011) A. Lavecchia et al. CURRENT MEDICINAL CHEMISTRY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer
- (2010) Jing-Yu Deng WORLD JOURNAL OF GASTROENTEROLOGY
- Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma
- (2009) JEEYUN LEE et al. APMIS
- STAT3 expression in gastric cancer indicates a poor prognosis
- (2008) Dae-Young Kim et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started